Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech bill sails through House

This article was originally published in The Tan Sheet

Executive Summary

The House Feb. 11 passes the National Nanotechnology Initiative Amendments Act, H.R. 554, to direct federal nanotechnology research, strengthen public-private partnerships through industry liaison groups and prioritize protecting public health and safety. An identical version of the bill cleared the House in 2008, but failed in the Senate (1"The Tan Sheet" Feb. 2, 2009, p. 16). In a same-day release, bill sponsor and Science and Technology Committee Chairman Bart Gordon says the legislation "will reduce the current uncertainty that inhibits commercial development of nanotechnology and will provide a sound basis for future rulemaking." The Tennessee Democrat adds that nanotechnology could be a $2.6 trillion industry by 2014

You may also be interested in...



House Shows Nanotech Safety Interest With Bill To Sharpen Federal Plan

The House Committee on Science and Technology will consider legislation crafted to provide strategic direction to the federal research program for nanotechnology

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel